Novel systemic therapy options for hepatocellular carcinoma

Cancer Journal

Volumn 10, Issue 2, 2004, Pages 97-103

  Cusnir, Mike ^a,b   Patt, Yehuda Z ^a,b  

^a Greenebaum Cancer Center ^*  (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Liver transplantation; Systemic therapy

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON; POLYPRENOIC ACID; CANCER VACCINE; RETINOID;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; DRUG TOLERABILITY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PATIENT SELECTION; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ADJUVANT CHEMOTHERAPY; ANIMAL; LIVER TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; HUMANS; INTERFERONS; LIVER NEOPLASMS; RETINOIDS;

EID: 4544265216     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200403000-00005     Document Type: Review

References (73)

1. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. DeVita VT, Hellman S, Rosenberg SA. Cancer, Principles and Practice of Oncology. Philadelphia: Lippincott Co., 2001.
3. Abeloff MD. Clinical Oncology. New York: Churchill Livingstone, 2000:xxix, 2963 p.
4. Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 2002;17:401-405.
5. Belghiti J, Panis Y, Farges O et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991;214:114-117.
6. Belghiti J, Regimbeau JM, Durand F et al. Resection of hepatocellular carcinoma: a European experience on 328 cases. Hepatogastroenterology 2002;49:41-46.
7. Durand F, Belghiti J. Liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 2002;49:47-52.
8. Tan KC, Rela M, Ryder SD et al. Experience of orthotopic liver transplantation and hepatic resection for hepatocellular carcinoma of less than 8 cm in patients with cirrhosis. Br J Surg 1995;82:253-256.
9. Tan K. Surgery for hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17[suppl 3]:5421-5423.
10. Lai EC, Lo CM, Fan ST et al. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998;133:183-188.
11. Huang YH, Wu JC, Lui WY et al. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. World J Surg 2000;24:551-555.
12. Ono T, Yamanoi A, Nazmy El Assal O et al. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 2001;91:2378-2385.
13. Shiratori Y, Shiina S, Teratani T et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138:299-306.
14. Schwanz JD, Schwartz M, Mandeli J et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002;3:593-603.
15. Wildi S, Kadry Z, Clavien PA. Neoadjuvant and adjuvant therapies for resectable hepatocellular carcinoma (HCC) and palliation strategies. Swiss Surg 2002;8:61-66.
16. Suzui M, Masuda M, Lim JT et al. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res 2002;62:3997-4006.
17. Muto Y, Moriwaki H, Ninomiya M et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996;334:1561-1568.
18. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046-1047.
19. Meyskens FL Jr, Jacobson J, Nguyen B et al. Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). Invest New Drugs 1998;16:171-173.
20. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-807.
21. Midgley R, Kerr DJ, Mirza N et al. A phase 11 dendritic cell (DC) immunotherapy trial for hepatocellular carcinoma (HC) [abstract 1901]. Proceedings of the American Society of Clinical Oncology 2002.
22. Kuang M, Peng BG, Lu MD. Phase II randomized trial of autologous formalin-fixed tumor vaccine for post-surgical recurrence of hepatocellular carcinoma. Clin Cancer Res 2004;10:1574-1579.
23. Kawata S, Yamasaki E, Nagase T et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: a randomized controlled trial. Br J Cancer 2001;84:886-891.
24. Lai CL, Wu PC, Chan GC et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer 1988;62:479-483.
25. Simonetti RG, Liberati A, Angiolini C et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997;8:117-136.
26. Lozano R, Patt Y, Hassan M et al. Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer) [abstr. 1025]. Proceedings of the American Society of Clinical Oncology 2000.
27. Patt YZ, Hassan MM, Aguayo A. Oral capecitabine for treatment of hepatocellular carcinoma, cholangiocarcinoma, and gall bladder cancer. Cancer 2004 (in press).
28. Capizzi R, Hann H-W, Feeney K et al. Gemcitabine (G), amifostine (A), and cisplatin (P) (GAP) treatment for unresectable hepatocellular carcinoma (HCC) [abstract 1113]. Proceedings of the American Society of Clinical Oncology 2000.
29. Fuloria J, Parikh P, Prabhakaran P et al. A multicemer, phase II trial of gemcitabine and cisplatin in unresectable hepatocellular carcinoma [abstract 1143]. Proceedings of the American Society of Clinical Oncology 2000.
30. Taieb J, Bonyhay L, Golli L et al. Gemcitabine plus oxaliplatin in inoperable hepatocellular carcinoma (HCC): a comparison of two schedules. Ann Oncol 2002;13:196.
31. Jones DV Jr, Lozano R, Hoque A et al. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996;14:2306-2310.
32. O'Reilly E, Stuart K, Kemeny N et al. A phase II trial of irinotecan (CPT-Il) in patients with advanced hepatocellular carcinomas (HCC) [abstr. 1026]. Proceedings of the American Society of Clinical Oncology 1998.
33. Patt YZ, Rowinsky E, O'Reilly E et al. Phase II trial of DX-8951f (exatecan mesylate) in hepatocellular carcinoma (HCC): a final analysis [abstract 555]. Proceedings of the American Society of Clinical Oncology 2002.
34. Tumolo S, Toffoli G, Bearz A et al. Oral idarubicin (IDA) for the treatment of hepatocellular carcinoma (HCC) [abstract 635]. Proceedings of the American Society of Clinical Oncology 2002.
35. Nagasue N, Ito A, Yukaya H, Ogawa Y. Estrogen receptors in hepatocellular carcinoma. Cancer 1986;57:87-91.
36. Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 1987;71:1213-1216.
37. Farinati F, Salvagnini M, de Maria N et al. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 1990;11:297-301.
38. Elba S, Giannuzzi V, Misciagna G et al. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroemerol 1994;26:66-68.
39. Martinez Cerezo FJ, Tomas A, Donoso L et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994;20:702-706.
40. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of lhe Liver Italian Programme). Lancet 1998;352:17-20.
41. Perrone F, Gallo C, Daniele B et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicemre randomised controlled trial. Curr Pharm Des 2002;8:1013-1019.
42. Villa E, Colantoni A, Camma C et al. Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol 2003;21:441-446.
43. Villa E, Dugani A, Fantoni E et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996; 56:3883-3885.
44. Villa E, Ferretli I, Grottola A et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001;84:881-885.
45. Uchino J, Une Y, Sato Y et al. Chemohormonal therapy of unresectable hepatocellular carcinoma. Am J Clin Oncol 1993;16:206-209.
46. Schachschal G, Lochs H, Plauth M. Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2000;12:281-284.
47. Chow PK, Tai BC, Tan CK et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002;36:1221-1226.
48. Grimaldi C, Bleiburg H, Gray F et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: Results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411-417.
49. Grosh W, Stac M, Alexander BI et al. Anastrozole (A) treatment of patients (pts) with advanced unresectable hepatocellular carcinoma (HCC). Proceedings of the American Society of Clinical Oncology 1999 (Abstract No. 1096).
50. Frizelle FA. Octreotide inhibits the growth and development of three types of experimental liver metastasis. Br J Surg 1995;82:1577.
51. Chen X, Liu Z, Ai Z. Antineoplastic mechanism of octreotide action in human hepatoma. Chin Med J (Engl) 2001;114:1167-1170.
52. Kouroumalis E, Skordilis P, Thermos K et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-t47.
53. Yuen MF, Poon RT, Lai CL et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-691.
54. Lai CL, Wu PC, Lok AS et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989;60:928-933.
55. Lai CL, Lau JY, Wu PC et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389-394.
56. A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. The Gastrointestinal Tumor Study Group. Cancer 1990;66:135-139.
57. Kountouras J, Boura P, Karolides A et al. Recombinant ot2 interferon (α-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC). Hepatogastroenterology 1995;42:31-36.
58. Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol 1996; 19:136-139.
59. Patt YZ, Hoque A, Roh M et al. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of Platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. Am J Clin Oncol 1999;22:209-213.
60. Leung TW, Patt YZ, Wan-Yee L et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-1681.
61. Leung TW, Tang AM, Zee B et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421-427.
62. Lau WY, Leung TW, Lai BS et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001;233:236-241.
63. Patt YZ, Hassan MM, Lozano RD et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant Interferon alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003;21:421-427.
64. Palmieri G, Montella L, Milo M et al. Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma. Am J Clin Oncol 2002; 25:224-226.
65. Yoshida T, Kaneko Y, Tsukamoto A et al. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res 1998;58:3751-3756.
66. Ahmed MH, Konno H, Nahar L et al. The angiogenesis inhibitor TNP-470 (AGM-1470) improves long-term survival of rats with liver metastasis. J Surg Res 1996;64:35-41.
67. Xia JL, Yang BH, Tang ZY et al. Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma. J Cancer Res Clin Oncol 1997;123:383-387.
68. Kong HL, Boyer MJ, Lim R et al. Phase II trial of thalidomide in unresectable hepatocellular carcinoma (HCC), a Cancer Therapeutics Research Group (CTRG) study [abstract 2282]. Proceedings of the American Society of Clinical Oncology 2001.
69. Lin AY, Brophy N, Fisher GA et al. Phase II study of thalidomide in patients (pts) with unresectable hepatocellular carcinoma (HCC) [abstract 22021. Proceedings of the American Society of Clinical Oncology 2002.
70. Patt Y, Hassan M, Lozano R et al. Phase II trial of Thalomid (thalidomide) for treatment of non-resectable hepatocellular carcinoma (HCC) [abstract 1035). Proceedings of the American Society of Clinical Oncology 2000.
71. Patt YZ, Hassan MM, Lozano RD et al. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000;23:319-321.
72. Chen C-S, Hillebrand D, Hill K, Lilly M. A pilot study of celecoxib combined with escalating doses of thalidomide for treatment of unresectable hepatocellular carcinoma (HCC) (abstract 2350]. Proceedings of the American Society of Clinical Oncology 2002.
73. Riestra S, Rodriguez M, Delgado M et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 1998;26:200-203.